Letter from the Editor

Dear Nephrology colleagues,

The annual meeting of the American Society of Nephrology Kidney Week 2022 was held this year from November 3-6, in Orlando, Florida, and attracted approximately 12,500 participants from around the world, including nephrology specialists, researchers, scientists, and other health care professionals. The conference featured presentations focusing on the latest advances in the management of patients with kidney diseases and related disorders.

One highlight of this meeting is always the ‘High-Impact Clinical Trials’ session, which this year provided further evidence that sodium–glucose co-transporter 2 (SGLT2) inhibitors are renoprotective across different categories of kidney diseases severity and aetiology, as well as diabetes status, some of which were simultaneously published in the New England Journal of Medicine. You can read about these updates in this peer-reviewed Congress Report.

In another study featured in this report, researchers found that intravenous fluid therapy with balanced crystalloid solution reduces the incidence of delayed graft function (DGF) compared with saline in patients receiving a kidney from a deceased donor. Important updates in the management of lupus nephritis are also described in this report. One study I was particularly excited about was the positive data from the Phase 2b study of encaleret in ADH1, which demonstrated that treatment with encaleret resulted in rapid and sustained restoration of normal mineral homeostasis by day 5 of therapy which sustained at 24 weeks, and encaleret was well-tolerated. We are hoping that encaleret could be the first therapy indicated for the treatment of ADH1, a condition caused by gain of function variants of the CASR gene.

But there are many more great new and updated results in this report, including new data on AKI, CKD, and news about the proof-of-concept study of the SmartPatch (SP) system, a wearable device to monitor serum potassium levels in haemodialysis patients. The field of nephrology remains a rapidly developing and diverse field.

Enjoy reading!

Dr Rachel Giles

 

Biography

Dr. Rachel H. Giles

Google Scholar: https://scholar.google.com/citations?user=5hjXkt4AAAAJ&hl=en

After her degrees in immunology and medicine at the University of California, Berkeley and UC San Francisco (USA), Dr. Giles was awarded her PhD cum laude in 1998 from the University of Leiden, the Netherlands, She performed post-docs at the University Medical Center Utrecht, and at the Hubrecht Institute, the Netherlands, in the lab of Prof. Hans Clevers and Prof. Emile Voest, and in 2003, she became Assistant Professor in the Internal Medicine at the UMC Utrecht (Prof. Voest), and was promoted to Associate Professor of Internal Medicine in 2006. Her clinical and fundamental research on kidney health is recognised internationally, particularly with regard to genetic renal syndromes.

Dr. Giles has co-authored >160 peer-reviewed papers, and her H-index is 62. She has served on the Dutch Kidney Foundation Scientific Board, and has been senior editor for 4 journals. In 2019 she joined Medicom Medical Publishers, where she is the Medical Science Officer. Dr Giles is also the co-founder and Chair of the International Kidney Cancer Coalition (ikcc.org).

Conflict of Interest Statement:

Dr Giles reports no conflicts of interest pertaining to this report.



Posted on 8 December, 2022